Congenital Myasthenic Syndrome: Long‐Term Outcomes up to 60 Years, Molecular Characterization, and Eight Novel Variants
Clinical Genetics · 2026
DOI: 10.1111/cge.70127 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Genetics, 2026. Verfasst von Ayfer Arduç Akçay und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Neurology, Department of Pediatrics, School of Medicine, Koç University, İstanbul, Türkiye. Hauptthemen laut MEDLINE: Myasthenic Syndromes, Congenital, Genetic Predisposition to Disease. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 48 Literaturangaben.
Abstract (Originalsprache)
Congenital myasthenic syndrome (CMS) refers to a rare heterogeneous group of hereditary disorders characterized by fatigue and muscle weakness due to impairment in neuromuscular transmission. A total of 40 genes have been identified in the pathogenesis of CMSs. The study assessed 22 patients (14 females and 8 males) with CMS of childhood onset with their phenotypes and genotypes. Genetic analysis revealed variations in the following eight genes: CHRNE , DOK7 , GFPT1 , COLQ , SLC25A1 , CHAT , MUSK , and MYO9A. Eight novel variations were detected involving SLC25A1 , MUSK , DOK7 , GFPT1 , and CHRNE . The median age was 14 years (range: 0.5–67 years). The median age of onset of symptoms was 8 months (range: 0–16 years). The longest time after the onset of symptoms was 62 years. The most common initial symptoms were weakness of extremities ( n = 9) and ptosis ( n = 8). Respiratory symptoms were present in 11 patients (50%), which showed progression, multiphasic disease course, and amelioration in 45.4%, 18.1%, and 36.3% of patients, respectively. Motor symptoms showed a progressive worsening in 68.1%, stationary course in 13.6%, multiphasic disease course in 13.6%, and amelioration in 4.5% of patients. Thanks to next‐generation sequencing, diagnoses of CMS have been increasing over the recent years; so has the number of novel variants.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pediatric Neurology, Department of Pediatrics, School of Medicine, Koç University, İstanbul, Türkiye.
- Department of Neurology, Koç University Hospital, İstanbul, Türkiye.
- Department of Medical Genetics, School of Medicine, Koç University, İstanbul, Türkiye.
- Department of Neurology, School of Medicine, Koç University, İstanbul, Türkiye.
ORCID-Profile: Ayfer Arduç Akçay, Gulshan Yunisova, Şahin Avcı, Ayşe Nur Özdağ Acarlı, Hülya Kayserili, Piraye Oflazer
Zitieren
APA
Akçay, A. A., Yunisova, G., Avcı, Ş., Acarlı, A. N. Ö., Kayserili, H., & Oflazer, P. (2026). Congenital Myasthenic Syndrome: Long‐Term Outcomes up to 60 Years, Molecular Characterization, and Eight Novel Variants. Clinical Genetics. https://doi.org/10.1111/cge.70127
Vancouver
Akçay AA, Yunisova G, Avcı Ş, Acarlı ANÖ, Kayserili H, Oflazer P. Congenital Myasthenic Syndrome: Long‐Term Outcomes up to 60 Years, Molecular Characterization, and Eight Novel Variants. Clinical Genetics. 2026. doi:10.1111/cge.70127
BibTeX
@article{Akay2026,
author = {Akçay, Ayfer Arduç and Yunisova, Gulshan and Avcı, Şahin and Acarlı, Ayşe Nur Özdağ and Kayserili, Hülya and Oflazer, Piraye},
title = {Congenital Myasthenic Syndrome: Long‐Term Outcomes up to 60 Years, Molecular Characterization, and Eight Novel Variants},
journal = {Clinical Genetics},
year = {2026},
doi = {10.1111/cge.70127}
}
EUVIMED